Korean Circ J.  2020 Apr;50(4):289-301. 10.4070/kcj.2019.0344.

Catheter Ablation for Brugada Syndrome

Affiliations
  • 1Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. anogami@md.tsukuba.ac.jp
  • 2Division of Cardiac Electrophysiology, Al Najaf Center for Cardiac Surgery and Trans-Catheter Therapy, Najaf, Iraq.

Abstract

Brugada syndrome (BrS) is an arrhythmogenic disease associated with an increased risk of ventricular fibrillation (VF) and sudden cardiac death (SCD). To date, the standard therapy for the prevention of SCD in BrS is the use of an implantable cardioverter-defibrillator (ICD) especially in patients who have experienced a prior cardiac arrest or syncopal events secondary to VF. However, ICDs do not prevent the occurrence of VF but react to defibrillate the VF episode, thereby preventing SCD. Often patients with recurrent VF have to be maintained on antiarrhythmic drugs that are effective but have remarkable adverse effects. An alternative therapy for BrS with recurrent VF is catheter ablation which emerged as an effective therapy in eliminating VF-triggering premature ventricular complexes in limited case series; however, there has been a remarkable progress in effectiveness of catheter ablation since epicardial substrate ablation was first applied in 2011 and such approach is now widely applicable.

Keyword

Brugada syndrome; Ventricular fibrillation; Radiofrequency ablation; VF-trigger; Substrate

MeSH Terms

Anti-Arrhythmia Agents
Brugada Syndrome*
Catheter Ablation*
Catheters*
Death, Sudden, Cardiac
Defibrillators, Implantable
Heart Arrest
Humans
Ventricular Fibrillation
Ventricular Premature Complexes
Anti-Arrhythmia Agents
Full Text Links
  • KCJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error